Are you affected by Acromegaly?

Then you could possibly be an eligible candidate for a clinical trial of Acromegaly treatment.

What is CAM2029Clinical Trials

Are you interested in taking part in the development of a potential new treatment for acromegaly?

The biopharmaceutical company Camurus is developing a new investigational formulation of the medicine octreotide, which has been a standard treatment for acromegaly for over 30 years.

This new investigational formulation of octreotide, currently called CAM2029, will be given once monthly as an injection under the skin (subcutaneous) using a pre-filled syringe or a pre-filled pen (allows auto-injection). To date, CAM2029 has been tested in healthy volunteers and subjects in 4 early stage clinical trials.

CAM2029 is currently being investigated in subjects with acromegaly in two large-scale, global, phase 3 clinical trials: HS-18-633 and HS-19-647.

Clinical trial HS-18-633

You may be eligible to participate in this clinical trial if:
You are age 18 years or older and you have been diagnosed with acromegaly
You are currently being treated with long-acting octreotide or lanreotide and have received treatment for at least 3 months

Your IGF-1 levels are well controlled and you have not undergone radiotherapy

IGF-1 cut off for 633 is IGF-1 ≤ to 1xULN

Clinical trial HS-19-647

You may be eligible to participate in this clinical trial if:
You are age 18 years or older and you have been diagnosed with acromegaly
You are currently being treated with long-acting octreotide or lanreotide and have received treatment for at least 3 months

You could have previously been treated in clinical trial HS-18-633

Your IGF-1 levels are not necessarily well controlled (IGF-1 levels above 1xULN but ≤ 2xULN) and you have possibly undergone radiotherapy

About Camurus

Camurus is a Swedish, science-led, biopharmaceutical company that is committed to developing and commercialising long-acting medicines for the treatment of severe and chronic conditions.

Camurus develops new treatments based on our proprietary FluidCrystal® drug delivery technologies and known active ingredients.

Camurus’ clinical pipeline includes products for the treatment of chronic serious diseases, such as acromegaly and neuroendocrine tumors, which are developed in-house and in collaboration with international pharmaceutical companies.